Management of DAAs Failure
If you have failure of plan A in treating a patient with chronic hepatitis C. What's your plan B
If you have failure of plan A in treating a patient with chronic hepatitis C. What's your plan B
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Pts With NS5A RAVs (%)<br />
Durability <strong>of</strong> Treatment-Emergent NS5A RAVs After<br />
Virologic <strong>Failure</strong><br />
• NS5A RAVs persisted in majority <strong>of</strong> pts for 96 wks<br />
100<br />
80<br />
98 100 98 100<br />
95<br />
86<br />
60<br />
40<br />
n/N =<br />
20<br />
0<br />
62/<br />
63<br />
58/<br />
58<br />
42/<br />
43<br />
VF Baseline FU-12 FU-24 FU-48 FU-96<br />
45/<br />
45<br />
Registry Study<br />
52/<br />
55<br />
50/<br />
58<br />
Dvory-Sobol H, et al. EASL 2015. Abstract O059.
Change language